Results for tag: "Rituximab Biosimilars"

Rituximab Biosimilars are biotechnological products that are similar to the original biologic drug, Rituximab. Rituximab is a monoclonal antibody used to treat certain types of cancer and autoimmune diseases. Biosimilars are developed using recombinant DNA technology and are designed to be highly similar to the original biologic drug. They are approved by the FDA and are used to provide an alternative to the original biologic drug. The Rituximab Biosimilars market is a rapidly growing sector of the biotechnology industry. It is driven by the increasing demand for cost-effective treatments for cancer and autoimmune diseases. The market is expected to continue to grow as more biosimilars are developed and approved by the FDA. Some companies in the Rituximab Biosimilars market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, Merck, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more